Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis.

ABSTRACT: No meta-analysis has analysed role of cagrilintide as weight-loss medication in obese individuals. Electronic databases were searched for RCTs involving obese individuals receiving cagrilintide or cagrilintide-2.4 mg with semaglutide-2.4 mg combination (Cagrisema) compared to placebo/active comparator. Primary outcomes were changes in body weight; secondary outcomes were alterations in glycemia, lipids, and adverse events. From 678 articles, data from 3 RCTs involving 430 individuals were analysed. At 20-32 weeks, patients receiving Cagrisema weekly had significantly greater percentage [mean difference (MD)-9.07% (95%CI: -11.91, -6.23); P < 0.00001;I ² = 96%] and absolute [MD-9.11 kg (95%CI: -12.84, -5.39); P < 0.00001; I ² = 98%] weight-lo

SUBMITTER: Dutta D 

PROVIDER: S-EPMC11642503 | biostudies-literature | 2024 Sep-Oct

REPOSITORIES: biostudies-literature